Ebola Raises Questions On Incentives For Drug, Vaccine Research
TIME: Ebola Should Change How We Fund Drugs for Emerging Disease
“Emerging and infectious diseases are having a moment for all the worst reasons, with credit due to the Ebola outbreak. But scientists studying other emerging diseases beyond Ebola are hopeful that the attention on the disease — and what can happen without available therapeutics — is here to stay. The fact that there are no drugs or vaccines approved for Ebola isn’t for a dearth of research, but rather because there’s scant financial incentive for pharmaceutical companies to take on the treatments…” (Sifferlin, 10/8).